FINCH THERAPEUTICS GROUP

YTD

ALL

Why Robinhood?

You can watch FNCH and buy or sell other stocks, ETFs, and their options commission-free!

About FNCH

Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms.

CEO

Matthew P. Blischak

CEOMatthew P. Blischak

Employees

Employees18

Headquarters

Somerville, Massachusetts

HeadquartersSomerville, Massachusetts

Founded

2014

Founded2014

Employees

Employees18

FNCH Key Statistics

Market cap

602.77M

Market cap602.77M

Price-Earnings ratio

-2.53

Price-Earnings ratio-2.53

Dividend yield

—

Dividend yield—

Average volume

107.56K

Average volume107.56K

High today

$12.75

High today$12.75

Low today

$12.52

Low today$12.52

Open price

$12.75

Open price$12.75

Volume

303.00

Volume303.00

52 Week high

$12.75

52 Week high$12.75

52 Week low

$0.2505

52 Week low$0.2505

People also own

Based on the portfolios of people who own FNCH. This list is generated using Robinhood data, and it’s not a recommendation.

FINCH THERAPEUTICS GROUP

Why Robinhood?

Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. Show more

FNCH Key Statistics

People also own

Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms.